ESMO 2021 Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously Donwload Press release (PDF) TG6002 en images

innovation box

Innovative technologies Push the boundaries of immunotherapy Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network. Discover our two therapeutic approaches Discover our technologies

TG4001 box

TG4001 A therapeutic vaccine in Phase II TG4001 targets HPV-induced anogenital cancers. More information


One patient, one cancer, one vaccine With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform. myvac® video Discover myvac®


A new generation of products These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer. Discover invir.IO™

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00


© 2021 Transgene - All rights reserved
Terms of use - Credits